A Shot At Bio ChIndia: India’s Biological E Tests Waters In China
This article was originally published in PharmAsia News
After bagging deals with GSK and Novartis, Indian vaccine maker Biological E is confidently setting sights on its next big target: China. Despite challenges aplenty, the company is banking on strong R&D and manufacturing to ease entry – but first it needs to find the right distributor.
You may also be interested in...
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.